Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Japan
/
Pharmaceuticals & Biotech
/
Eisai
4523
Eisai
Japan HTA Review And MFN Proposals Will Squeeze Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
21 Jun 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
JP¥3,300.00
41.7% overvalued
intrinsic discount
20 Aug
JP¥4,676.00
Loading
1Y
-24.2%
7D
0.8%
Author's Valuation
JP¥3.3k
41.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
JP¥3.3k
41.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
824b
2014
2017
2020
2023
2025
2026
2028
Revenue JP¥823.9b
Earnings JP¥44.4b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
3.73%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.72%
Calculation
JP¥44.37b
Earnings '28
x
24.00x
PE Ratio '28
=
JP¥1.06t
Market Cap '28
JP¥1.06t
Market Cap '28
/
281.39m
No. shares '28
=
JP¥3.78k
Share Price '28
JP¥3.78k
Share Price '28
Discounted to 2025 @ 4.72% p.a.
=
JP¥3.30k
Fair Value '25